Israel - English - Ministry of Health

kamada ltd, israel - factor viii; von willebrand factor - powder for solution for injection - factor viii 1000 iu/vial; von willebrand factor 2600 iu/vial - von willebrand factor and coagula-tion factor viii in combination - von willebrand factor and coagula-tion factor viii in combination - treatment and prophylaxis of bleeding with haemophilia a (congenital factor viii deficiency).

Singapore - English - HSA (Health Sciences Authority)

wellchem pharmaceuticals pte ltd - factor ii; factor ix; factor vii; factor x; protein c; protein s - injection, powder, for solution - factor ii 280 - 760 iu/vial; factor ix 500 iu/vial; factor vii 180 - 480 iu/vial; factor x 360 - 600 iu/vial; protein c 260 - 620 iu/vial; protein s 240 - 640 iu/vial

Israel - English - Ministry of Health

medici medical ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 1500 iu/dose - factor viii inhibitor bypassing activity - factor viii inhibitor bypassing activity - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a . fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

alhayat pharmaceuticals spain - 1 kit [1 lyophilised glass vial+1 pf syringe solvent of 10 ml+1 vial adaptor+1 syringe filter+2 alcohol swabs+1 butterfly needle - injection - factor ix grifols® 50 iu/ml (250 iu/5 ml) - cardiovascular system-antifibrinolytics , haemostatics

European Union - English - EMA (European Medicines Agency)

sanquin plasma products b.v. - human coagulation factor ix - hemophilia b - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia b (congenital factor ix deficiency).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - nonacog alfa, quantity: 3000 iu - injection, powder for - excipient ingredients: polysorbate 80; sucrose; histidine; glycine - benefix is indicated for the control and prevention of haemorrhagic episodes in patients with haemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings. benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii, vii and x), nor for the treatment of haemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin induced anti-coagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - coagulation factor ix human (unii: 6u90y1795t) (coagulation factor ix human - unii:6u90y1795t) - coagulation factor ix human 300 [iu] in 1 ml

United States - English - NLM (National Library of Medicine)

baxalta incorporated - coagulation factor ix human (unii: 6u90y1795t) (coagulation factor ix human - unii:6u90y1795t) - coagulation factor ix human 30 [iu] in 1 ml

Malta - English - Medicines Authority

baxalta innovations gmbh industriestrasse 67, 1221, vienna, austria - factor ii, prothrombin, factor ix, human, factor x, factor vii - powder and solvent for solution for injection - factor ii (prothrombin) 24-45 iu/mg factor ix, human 30 iu/mg factor x, human 30 iu/mg factor vii, human 25 iu/mg - antihemorrhagics

Malta - English - Medicines Authority

kedrion s.p.a loc. ai conti, 55051 castelvecchio pascoli, barga - lucca, italy - factor ix, human - powder and solvent for solution for infusion - factor ix, human 500 iu - antihemorrhagics